Literature DB >> 26112020

18F-Fluoromisonidazole Quantification of Hypoxia in Human Cancer Patients Using Image-Derived Blood Surrogate Tissue Reference Regions.

Mark Muzi1, Lanell M Peterson2, Janet N O'Sullivan3, James R Fink2, Joseph G Rajendran2, Lena J McLaughlin2, John P Muzi1, David A Mankoff4, Kenneth A Krohn2.   

Abstract

UNLABELLED: (18)F-fluoromisonidazole ((18)F-FMISO) is the most widely used PET agent for imaging hypoxia, a condition associated with resistance to tumor therapy. (18)F-FMISO equilibrates in normoxic tissues but is retained under hypoxic conditions because of reduction and binding to macromolecules. A simple tissue-to-blood (TB) ratio is suitable for quantifying hypoxia. A TB ratio threshold of 1.2 or greater is useful in discriminating the hypoxic volume (HV) of tissue; TBmax is the maximum intensity of the hypoxic region and does not invoke a threshold. Because elimination of blood sampling would simplify clinical use, we tested the validity of using imaging regions as a surrogate for blood sampling.
METHODS: Patients underwent 20-min (18)F-FMISO scanning during the 90- to 140-min interval after injection with venous blood sampling. Two hundred twenty-three (18)F-FMISO patient studies had detectable surrogate blood regions in the field of view. Quantitative parameters of hypoxia (TBmax, HV) derived from blood samples were compared with values using surrogate blood regions derived from the heart, aorta, or cerebellum. In a subset of brain cancer patients, parameters from blood samples and from the cerebellum were compared for their ability to independently predict outcome.
RESULTS: Vascular regions of heart showed the highest correlation to measured blood activity (R(2) = 0.84). For brain studies, cerebellar activity was similarly correlated to blood samples. In brain cancer patients, Kaplan-Meier analysis showed that image-derived reference regions had predictive power nearly identical to parameters derived from blood, thus obviating the need for venous sampling in these patients.
CONCLUSION: Simple static analysis of (18)F-FMISO PET captures both the intensity (TBmax) and the spatial extent (HV) of tumor hypoxia. An image-derived region to assess blood activity can be used as a surrogate for blood sampling in quantification of hypoxia.
© 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Entities:  

Keywords:  18F-FMISO; PET; hypoxia; quantitation

Mesh:

Substances:

Year:  2015        PMID: 26112020      PMCID: PMC4526410          DOI: 10.2967/jnumed.115.158717

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  30 in total

1.  Determining hypoxic fraction in a rat glioma by uptake of radiolabeled fluoromisonidazole.

Authors:  J S Rasey; J J Casciari; P D Hofstrand; M Muzi; M M Graham; L K Chin
Journal:  Radiat Res       Date:  2000-01       Impact factor: 2.841

2.  Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole.

Authors:  W J Koh; J S Rasey; M L Evans; J R Grierson; T K Lewellen; M M Graham; K A Krohn; T W Griffin
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

3.  A radiosynthesis of fluorine-18 fluoromisonidazole.

Authors:  J R Grierson; J M Link; C A Mathis; J S Rasey; K A Krohn
Journal:  J Nucl Med       Date:  1989-03       Impact factor: 10.057

4.  Enhanced binding of the hypoxic cell marker [3H]fluoromisonidazole in ischemic myocardium.

Authors:  G V Martin; J H Caldwell; J S Rasey; Z Grunbaum; M Cerqueira; K A Krohn
Journal:  J Nucl Med       Date:  1989-02       Impact factor: 10.057

5.  Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia.

Authors:  J S Rasey; W J Koh; J R Grierson; Z Grunbaum; K A Krohn
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-11       Impact factor: 7.038

6.  Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells.

Authors:  J S Rasey; Z Grunbaum; S Magee; N J Nelson; P L Olive; R E Durand; K A Krohn
Journal:  Radiat Res       Date:  1987-08       Impact factor: 2.841

7.  Characteristics of the binding of labeled fluoromisonidazole in cells in vitro.

Authors:  J S Rasey; N J Nelson; L Chin; M L Evans; Z Grunbaum
Journal:  Radiat Res       Date:  1990-06       Impact factor: 2.841

8.  Synthesis and characterization of congeners of misonidazole for imaging hypoxia.

Authors:  Z Grunbaum; S J Freauff; K A Krohn; D S Wilbur; S Magee; J S Rasey
Journal:  J Nucl Med       Date:  1987-01       Impact factor: 10.057

9.  Mathematical modelling of oxygen supply and oxygenation in tumor tissues: prognostic, therapeutic, and experimental implications.

Authors:  F L Degner; R M Sutherland
Journal:  Int J Radiat Oncol Biol Phys       Date:  1988-08       Impact factor: 7.038

10.  [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression.

Authors:  J G Rajendran; D C Wilson; E U Conrad; L M Peterson; J D Bruckner; J S Rasey; L K Chin; P D Hofstrand; J R Grierson; J F Eary; K A Krohn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-03-11       Impact factor: 9.236

View more
  19 in total

1.  Imaging Hypoxia with ¹⁸F-Fluoromisonidazole: Challenges in Moving to a More Complicated Analysis.

Authors:  Mark Muzi; Kenneth A Krohn
Journal:  J Nucl Med       Date:  2016-02-18       Impact factor: 10.057

2.  Predicting hypoxia status using a combination of contrast-enhanced computed tomography and [18F]-Fluorodeoxyglucose positron emission tomography radiomics features.

Authors:  Mireia Crispin-Ortuzar; Aditya Apte; Milan Grkovski; Jung Hun Oh; Nancy Y Lee; Heiko Schöder; John L Humm; Joseph O Deasy
Journal:  Radiother Oncol       Date:  2017-12-19       Impact factor: 6.280

Review 3.  Integrating mechanism-based modeling with biomedical imaging to build practical digital twins for clinical oncology.

Authors:  Chengyue Wu; Guillermo Lorenzo; David A Hormuth; Ernesto A B F Lima; Kalina P Slavkova; Julie C DiCarlo; John Virostko; Caleb M Phillips; Debra Patt; Caroline Chung; Thomas E Yankeelov
Journal:  Biophys Rev (Melville)       Date:  2022-05-17

4.  Quantitative [18F]FMISO PET Imaging Shows Reduction of Hypoxia Following Trastuzumab in a Murine Model of HER2+ Breast Cancer.

Authors:  Anna G Sorace; Anum K Syed; Stephanie L Barnes; C Chad Quarles; Violeta Sanchez; Hakmook Kang; Thomas E Yankeelov
Journal:  Mol Imaging Biol       Date:  2017-02       Impact factor: 3.488

5.  ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI.

Authors:  Elizabeth R Gerstner; Zheng Zhang; James R Fink; Mark Muzi; Lucy Hanna; Erin Greco; Melissa Prah; Kathleen M Schmainda; Akiva Mintz; Lale Kostakoglu; Edward A Eikman; Benjamin M Ellingson; Eva-Maria Ratai; A Gregory Sorensen; Daniel P Barboriak; David A Mankoff
Journal:  Clin Cancer Res       Date:  2016-05-16       Impact factor: 12.531

Review 6.  The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective.

Authors:  Robert H Press; Hui-Kuo G Shu; Hyunsuk Shim; James M Mountz; Brenda F Kurland; Richard L Wahl; Ella F Jones; Nola M Hylton; Elizabeth R Gerstner; Robert J Nordstrom; Lori Henderson; Karen A Kurdziel; Bhadrasain Vikram; Michael A Jacobs; Matthias Holdhoff; Edward Taylor; David A Jaffray; Lawrence H Schwartz; David A Mankoff; Paul E Kinahan; Hannah M Linden; Philippe Lambin; Thomas J Dilling; Daniel L Rubin; Lubomir Hadjiiski; John M Buatti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-06-30       Impact factor: 7.038

7.  Galectin expression detected by 68Ga-galectracer PET as a predictive biomarker of radiotherapy resistance.

Authors:  Dehua Lu; Haoyi Zhou; Nan Li; Yanpu Wang; Ting Zhang; Fei Wang; Ning Liu; Hua Zhu; Jinming Zhang; Zhi Yang; Zhaofei Liu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-02-02       Impact factor: 10.057

8.  Impact of tissue transport on PET hypoxia quantification in pancreatic tumours.

Authors:  Edward Taylor; Jennifer Gottwald; Ivan Yeung; Harald Keller; Michael Milosevic; Neesha C Dhani; Iram Siddiqui; David W Hedley; David A Jaffray
Journal:  EJNMMI Res       Date:  2017-12-22       Impact factor: 3.138

9.  Glioma FMISO PET/MR Imaging Concurrent with Antiangiogenic Therapy: Molecular Imaging as a Clinical Tool in the Burgeoning Era of Personalized Medicine.

Authors:  Ramon F Barajas; Kenneth A Krohn; Jeanne M Link; Randall A Hawkins; Jennifer L Clarke; Miguel H Pampaloni; Soonmee Cha
Journal:  Biomedicines       Date:  2016-10-31

10.  Noninvasive PET Imaging and Tracking of Engineered Human Muscle Precursor Cells for Skeletal Muscle Tissue Engineering.

Authors:  Deana Haralampieva; Thomas Betzel; Ivana Dinulovic; Souzan Salemi; Meline Stoelting; Stefanie D Krämer; Roger Schibli; Tullio Sulser; Christoph Handschin; Daniel Eberli; Simon M Ametamey
Journal:  J Nucl Med       Date:  2016-05-19       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.